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Abstract
AIM
To determine the existence of a common pathological link 
between dementia and osteoporosis through reviewing 
the current evidence base. 
METHODS
This paper reviews the current literature on osteoporosis 
and dementia in order to ascertain evidence of a common 
predisposing aetiology. A literature search of Ovid MED-
LINE (1950 to June 2016) was conducted. The keywords 
“osteoporosis”, “osteoporotic fracture”, “dementia” and 
“Alzheimer’s disease” (AD) were used to determine the 
theoretical links with the most significant evidence base 
behind them. The key links were found to be vitamins 
D and K, calcium, thyroid disease, statins, alcohol and 
sex steroids. These subjects were then searched in 
combination with the previous terms and the resulting 
papers manually examined. Theoretical, in vitro  and in 
vivo research were all used to inform this review which 
focuses on the most well developed theoretical common 
causes for dementia (predominantly Alzheimer’s type) and 
osteoporosis.
RESULTS
Dementia and osteoporosis are multifaceted disease 
processes with similar epidemiology and a marked increase 
in prevalence in elderly populations. The existence of 
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a common link between the two has been suggested 
despite a lack of clear pathological overlap in our current 
understanding. Research to date has tended to be 
fragmented and relatively weak in nature with multiple 
confounding factors reflecting the difficulties of in vivo 
experimentation in the population of interest. Despite 
exploration of various possible mechanisms in search 
for a link between the two pathologies, this paper found 
that it is possible that these associations are coincidental 
due to the nature of the evidence available. One finding 
in this review is that prior investigation into common 
aetiologies has found raised amyloid beta peptide levels in 
osteoporotic bone tissue, with a hypothesis that amyloid 
beta disorders are systemic disorders resulting in differing 
tissue manifestations. However, our findings were that the 
most compelling evidence of a common yet independent 
aetiology lies in the APOE4 allele, which is a well-established 
risk for AD but also carries an independent association with 
fracture risk. The mechanism behind this is thought to be 
the reduced plasma vitamin K levels in individuals exhibiting 
the APOE4 allele which may be amplified by the nutritional 
deficiencies associated with dementia, which are known to 
include vitamins K and D. The vitamin theory postulates that 
malnutrition and reduced exposure to sunlight in patients 
with AD leads to vitamin deficiencies. 
CONCLUSION
Robust evidence remains to be produced regarding 
potential links and regarding the exact aetiology of 
these diseases and remains relevant given the burden 
of dementia and osteoporosis in our ageing population. 
Future research into amyloid beta, APOE4 and vitamins K 
and D as the most promising aetiological links should be 
welcomed. 
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Calcium; Statins; Alcohol; Sex steroids
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Core tip: A potential pathological link between osteo-
porosis and dementia has been explored in observational 
studies, but there exists a lack of large scale randomised 
controlled trials. We hypothesise that dementia and 
osteoporosis have common yet independent aetiologies. 
The most compelling evidence lies in the APOE4 allele, a 
well-established risk factor for Alzheimer’s disease. APOE4 
is associated with fracture, independent of dementia and 
falling. The mechanism behind this is postulated to be 
reduced plasma vitamin K levels in individuals exhibiting 
the APOE4 allele. This may be augmented by the nu-
tritional deficiencies associated with dementia, known to 
include vitamins K and D. 
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INTRODUCTION
Dementia and osteoporosis are complex disease pro­
cesses with similar epidemiology. Alzheimer’s disease 
(AD) is the most common form of dementia and increases 
from 16% in 75­year­old to 84­year­old to 48% in over­
85s[1]. Osteoporosis affects 25% of women and 10% of 
men over 60[2]. The two diseases co­exist in a subsection 
of the population, especially amongst females[3]. Indeed, 
an odds ratio of 6.9 for fracture prevalence between 
people with and without AD has been reported[4]. Thus 
a common link has been suggested despite no apparent 
pathological overlap.
The pathogenesis of AD lies in three complex mecha­
nisms[5]. The development of amyloid senile plaques 
causes neuronal death and phosphorylation of Tau 
proteins. Tau disassembles the microtubules resulting 
in neurofibrillary tangles and ultimately neuronal degen­
eration. Amyloid and Tau localise in the synapses, causing 
excessive calcium entry into post­synaptic neurons, 
necrosis and apoptosis. Despite extensive research into 
the disease, current treatment options are limited by their 
cost and efficacy. Their action lies in palliation of symptoms 
and most are only effective in a subsection of AD sufferers. 
Osteoporosis is a progressive skeletal disease chara­
cterised by reduced bone density and micro­architectural 
bone destruction. This leads to increased bone fragility 
and susceptibility to fracture. Like dementia, the patho­
physiology of osteoporosis is multifactorial and extends 
far past the traditional theory of nutritional calcium 
depletion. Indeed, both diseases have been associated 
with a number of other metabolic disturbances such as 
decreased vitamin D concentration and elevated serum 
parathyroid hormone, in addition to postulated common 
genetic variations such as the APOE4 allele[2]. 
The burden of elderly care is a significant challenge 
to healthcare systems throughout the world and will 
only continue to grow in the coming decades. AD is the 
leading cause of loss of autonomy and independency 
in the elderly, and is associated with a number of 
comorbidities[6]. Osteoporotic fractures have huge impact 
in terms of morbidity and mortality. Both diseases form 
part of the frailty syndrome, a collection of signs and 
symptoms associated with significant disability and public 
expenditure[7]. Here we hypothesize that osteoporosis 
and dementia share a common predisposing aetiology. 
We propose that this is multifactorial, involving genetic, 
metabolic, endocrine and environmental factors. Elucidation 
of a common link between the two diseases could prove 
vital in the development of novel treatments for these 
complex medical and social problems. 
MATERIALS AND METHODS
A comprehensive literature search of Ovid MEDLINE (1950 
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to June 2016) was conducted. The keywords “oste­
oporosis”, “osteoporotic fracture”, “dementia” and 
“Alzheimer’s disease” were used initially to determine 
the theoretical links with the most significant evidence 
base behind them. From manual study of key papers 
the lead investigators selected these to be vitamins D 
and K, calcium, thyroid disease, statins, alcohol and sex 
steroids. These subjects were searched in combination 
with the previous terms. Manual examination of titles 
and abstracts was used to exclude irrelevant articles. 
Theoretical, in vitro and in vivo research were all used 
to inform this review which focuses on the most well 
developed theoretical common causes for dementia 
(predominantly Alzheimer’s type) and osteoporosis.
RESULTS
Vitamin D 
Approximately 1 billion adults are vitamin D deficient 
worldwide, and the prevalence is especially marked 
in older people, ranging from 50%­80%[5]. Vitamin D 
has long been known for its effects on phosphocalcic 
metabolisms and bone[5], thus vitamin D deficiency is 
well established as a risk factor for the development 
of osteoporosis[8]. In contrast, the association between 
vitamin D and dementia requires clarification. 
In 1995, Kipen et al[8] found significantly lower vitamin 
D in women with dementia compared to cognitively­
intact controls. A subsequent cross­sectional study found 
a vitamin D deficiency of < 10 ng/mL doubled the risk 
of cognitive impairment[9]. A similar association between 
severe vitamin D deficiency (here defined as < 25 nmol/L 
at baseline) and mild cognitive impairment has been seen 
in elderly subjects over 65 years of age[10]. 
A recent large Danish prospective study looked at 
participants who were free of cognitive impairment 
at enrolment and found that a decline in serum levels 
of vitamin D were associated with increased risk of 
participants developing AD[11]. A more diverse American 
prospective study with a shorter length of follow up 
also found an association between baseline vitamin D 
deficiency (defined by the authors as serum levels < 50 
nmol/L) and likelihood of participants developing AD and 
other all­cause dementias, an association that remained 
despite adjustment for mediators such as diabetes and 
hypertension[12]. Both these studies looked at healthy 
participants who were ambulatory at enrolment[11,12]. 
However reduced exposure to sunlight in patients with 
AD has been implicated as the main cause of vitamin 
D deficiency in patients with dementia[13]. Patients with 
dementia are often immobile or housebound, and may be 
unable to gain sufficient sunlight exposure. Furthermore, 
generalised malnutrition either due to changes in 
functional ability, appetite disturbance, or disease may 
compound this problem. 
In addition to environmental and functional changes, 
a decline in renal function accompanies the process 
of aging with the incidence of chronic kidney disease 
quoted as up to 35.8% in the geriatric population[14]. 
Chronic renal disease results in impaired 1,25 dihydr­
oxycholecalciferol production, the physiologically active 
metabolite within the body. Patients with suboptimal 
production of 1,25 dihydroxycholecalciferol may have 
this confirmed by low serum levels, and evidence of a 
secondary hyperparathyroidism[15]. 
Aside from well­established physiological effects on 
bone metabolism, vitamin D has been found to play a 
pivotal role in both the normal function and protection 
of the central nervous system (CNS). As a neurosteroid 
hormone, vitamin D receptors are found in the neurons 
and glial cells of the CNS[5]. The binding of 1,25 dihy­
droxycholecalciferol to these receptors results in a nu­
mber of neuroprotective mechanisms. These can be 
categorised as direct, immune and homeostatic.
Directly, vitamin D inhibits the synthesis of nitric oxide 
synthase, an enzyme which promotes neuron alterations, 
and increases the synthesis of neurotrophic agents 
such as nerve growth factor[5]. In addition, neuron­
glial cell cultures treated with vitamin D show increased 
expression of genes known to limit the progression of 
AD[16]. Vitamin D is also known to increase the number 
of macrophages and leukocytes in the brain. In vitro 
studies of macrophages from AD patients showed that 
stimulation with vitamin D increased phagocytosis and 
clearance of amyloid[17]. Vitamin D plays an important 
role in the homeostasis of calcium and the avoidance of 
hyperparathyroidism by upregulating calcium channels 
and the synthesis of calcium­binding proteins[5]. The 
importance of calcium and parathyroid status is discussed 
later. 
Despite evidence in vitro, conclusive evidence of a link 
between vitamin D and dementia in patients is lacking 
(Table 1). In cross­sectional studies, vitamin D deficiency 
has been shown to double the risk of presenting with 
cognitive impairment[9]. However, the nature of cross­
sectional studies means that no cause and effect link 
can be made. Clearly, dementia may be the cause of 
reduced mobility and therefore reduced exposure to 
sunlight. A recent BMJ editorial criticised the perceived 
reliance on cross­sectional studies in relation to vitamin 
D as an aetiological factor in AD. It cited “a range of 
interpretational difficulties” such as reverse causality, 
confounding, classification bias and differences in assay 
methods[18].
Nevertheless, in longitudinal studies, low baseline 
vitamin D levels have been found to predict incident 
cognitive decline in the elderly. A study of 858 Italians 
over the age of 65 showed that those who were “severely 
deficient” in vitamin D had a 1.6­fold increased risk of a 
substantial cognitive decline over 6 years, thus providing 
a temporal association[19]. Another longitudinal study 
looking at time to progression to AD along with vitamin 
D treatment status, found that time to progression was 
longer in those treated with vitamin D (5.4 ± 0.4 years, P 
= 0.003) than in those who were not supplemented (4.4 
± 0.16 years, P = 0.003) but only in those who went on 
to develop severer manifestations of the disease[20]. This 
study however was limited again by an observational 
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study design and exclusion of some confounders from 
analysis, for example treatment with psychotropic 
medication[20]. Pre­post studies, where cognitive function 
was measured before and after supplementation of 
vitamin D, found an improvement in cognition concomitant 
with the increase in vitamin D concentrations[5]. There is 
only one, small randomised controlled trial on this topic, 
where 32 individuals with mild to moderate AD received 
low­dose vitamin D supplementation for 8 wk, before 
being randomised to either continue with the low dose (plus 
placebo) or to receive an additional high­dose supplement 
for a further 8 wk. Cognition was tested using a number of 
validated scales. Despite promising results from a smaller 
pilot study, the authors found that supraphysiological 
doses of vitamin D were no better than physiological 
doses at improving cognition or disability in this group, but 
acknowledge the limitations of such a small sample size[21]. 
Vitamin K
Vitamin K is the collective term for a group of fat­solu­
ble vitamins responsible for gamma­carboxylation of 
glutamate at various sites in the body. In the liver, vitamin 
K plays a vital role in the modification of prothrombin and 
other proteins responsible for haemostasis[1]. In addition, 
vitamin K promotes bone health by means of site­
specific carboxylation of osteocalcin (a marker of bone 
formation) and other bone matrix proteins such as matrix 
Gla­protein and protein S[22]. In vitamin K deficiency, 
undercarboxylated osteocalcin is associated with 
osteoporosis and increased risk of fracture[1]. A meta­
analysis of 3 trials involving patients with neurological 
disease (AD, stroke and Parkinson’s Disease) showed 
that when vitamin K is replaced, there is a decreased risk 
of fractures compared to non­treatment[23]. 
As with vitamin D, the link between vitamin K and 
osteoporosis is well­established, whilst any connection 
to dementia remains both multifactorial and largely 
theoretical. Numerous observational studies from Japan 
have indicated that vitamin K deficiencies contribute to 
reduced bone mineral density in patients with AD[22]. 
A number of reasons have been postulated for the 
association between vitamin K deficiency and dementia 
including that of reverse causality.
It is plausible that, rather than vitamin K deficiency 
causing dementia, it is the dementia which affects 
vitamin K levels through malnutrition. Suboptimal dietary 
intake is evident even in the early stages of AD compared 
to cognitively intact age­matched controls[24]. In humans, 
vitamin K1 is dietary, whilst K2 is synthesised by gut 
bacteria[3]. In a cross­sectional study of 100 women with 
varying degrees of AD, BMI, bone mineral density and 
vitamin K1 levels were significantly lower in severe AD 
compared to mild AD[3]. However, vitamin K2 levels were 
not significantly decreased, indicating a nutritional cause. 
Another study analysed the dietary vitamin K intakes 
of 31 patients with mild AD, compared to 31 controls. 
Table 1  Studies investigating the association between vitamin D and cognition
Study design Ref. Population Results
Cross-sectional study [88] 80 community-dwelling women
40 with mild AD
40 cognitively-intact
Vitamin D deficiency was associated with impairment on two 
of four measures of cognitive performance
[89] 32 community-dwelling patients Significant positive correlation between vitamin D 
concentrations and MMSE scores
[90] 9556 community-dwelling patients Lower 25(OH)D levels were not associated with impaired 
performance on various psychometric measures
[91] 225 older outpatients diagnosed as having probable 
AD
Significant positive association between MMSE test scores and 
serum 25-hydroxyvitamin D(3) levels
Case-control study [92] 5596 community-dwelling women Significant positive association between vitamin D intakes and 
cognitive performance
[93] 69 community-dwelling patients A significant negative correlation between dietary intake of 
vitamin D and poor performance on cognitive tests
[94] 148 community-dwelling patients No significant positive association between cognitive 
performance and serum 25-hydroxyvitamin D(3) levels
Longitudinal study [95] 1138 community-dwelling men Independent association between lower vitamin D levels and 
odds of cognitive decline
[19] 175 community-dwelling patients 1.60-fold risk of losing at least 3 points on MMSE in 6 yr with 
low baseline vitamin D
Pre-post study [96] 63 frail nursing home residents
25 in intervention group
38 in control group
No treatment-induced improvement in ambulation, cognition 
or behaviour was observed
[21] 13 community-dwelling patients with mild to 
moderate AD
Significant improvement in ADAs-cog score
Randomised controlled 
trial
[21] 32 community-dwelling patients with mild to 
moderate AD
16 in intervention group
16 in control group
Neither cognition nor disability changed significantly after 
high-dose D
AD: Alzheimer’s disease.
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Vitamin K intakes were significantly less in patients with 
AD, even after adjusting for energy intake[25].
Nevertheless, vitamin K does also appear to have a 
direct effect on the brain. Vitamin K­dependent gamma­
carboxylation of glutamate in the liver and bone has 
already been discussed. This process is also apparent in 
the brain, by which growth­arrest­specific gene (Gas6) 
is biologically activated. Yagami et al[26] investigated the 
effect of Gas6 in primary cultures of rat cortical neurons. 
Gas6 was shown to protect against AD by the rescue of 
cortical neurons from amyloid­induced apoptosis[26]. In 
addition, vitamin K is involved in sphingolipid synthesis. 
Sphingolipids are an important constituent of the myelin 
sheath and the neuron cell membrane, and alterations 
in sphingolipid metabolism have been identified in the 
brains of patients with mild AD[25]. 
Alternatively, dementia and vitamin K deficiency may 
share a common cause. As previously discussed, apoli­
poprotein E4 (APOE4) is an allele that has been well­
established as a risk factor for AD[3]. APOE is found in 
chylomicrons which bind to vitamin K in plasma[1]. APOE 
binds to a hepatic LDL receptor and LDL receptor­related 
protein (LRP); the variant APOE4 binds particularly quickly, 
thus reducing plasma vitamin K levels[1]. The concentration 
of vitamin K is therefore lower in the circulating blood of 
APOE4 carriers[1] and women expressing the APOE4 allele 
have been shown to have a significantly increased risk 
of osteoporotic hip fractures compared with those with 
other APOE genotypes[27]. Another genotype, consisting of 
two copies of the apolipoprotein allele E2, has also been 
associated with increased frequency of vertebral fractures, 
suggesting further that apolipoprotein polymorphisms may 
play a role in bone mineral density and fracture risk[28].
Although the association between vitamin K and 
dementia appears strong, there is little outside of cell 
work to prove a causal relationship. The evidence thus 
far lies in observational studies[22] and a small number 
of randomised controlled trials in which vitamin K supple­
mentation has been proven to reduce the risk of fractures 
in patients with neurological disease[23]. This effect is 
assumed to be bone­mediated, and the possibility of 
improved cognitive function is not explored. 
Calcium and hyperparathyroidism
Calcium has long been known to contribute to bone 
health. In combination with vitamin D, calcium promotes 
osteoblast differentiation and formation of mineralised 
bone, thus impairment in calcium signalling can contribute 
to the pathophysiology of osteoporosis[29]. Likewise, the 
role of calcium homeostasis in the pathophysiology of 
dementia has been extensively investigated for almost 
three decades. The “calcium hypothesis” of the late 
1980s[30] postulates that “in the aging brain, transient 
or sustained increases in the average concentration of 
intracellular free calcium contribute to impaired function, 
eventually leading to cell death”. This hypothesis was 
supported by a range of animal and human studies, the 
earliest of which have been well­described by Disterhoft 
et al[30]. For example, administration of magnesium, a 
calcium channel antagonist, to aging rats was shown 
to reduce calcium influx in hippocampal neurons and 
reverse functional and learning difficulties. Similarly, 
nimodipine, an isopropyl calcium channel antagonist that 
readily crosses the blood­brain barrier, was found by a 
recent Cochrane review to be of “some benefit in the 
treatment of patients with features of dementia due to 
unclassified disease or to AD, cerebrovascular disease, or 
mixed Alzheimer’s and cerebrovascular disease” although 
the authors stressed this benefit could only be applied to 
short­term outcomes[31]. 
The role of calcium in the pathophysiology of im­
paired cognition is complex. Calcium is required for the 
function of all cells in the body, including neurons. The 
neurons of aged animals have been found to exhibit 
enhanced calcium activity compared to their younger 
counterparts[32]. This has been attributed to an excess 
of calcium influx via voltage­gated calcium channels. 
Indeed, an increased density of these channels has been 
positively correlated with cognitive decline in animals. 
Further, in humans, enhanced intracellular calcium 
release from the endoplasmic reticulum has been found 
in the ageing brain, and research into this phenomenon 
continues[32]. 
To propose that changes in calcium transport and 
metabolism forms the basis of link between osteoporosis 
and dementia seems counterintuitive, as the former 
may result from falling calcium levels, whist the latter 
has been attributed to high intracellular calcium. One 
possible mechanism is that calcium deficiency and the 
resultant secondary hyperparathyroidism results in bone 
loss whilst shifting calcium from the skeleton to the soft 
tissue, and from the extracellular to the intracellular 
compartments[33]. Indeed a recent cross­sectional 
study has found association between high levels of PTH 
with low bone mineral density, which persisted even in 
participants where serum calcium levels were not overtly 
deficient[34]. 
Increased parathyroid activity is well known to be 
associated with impaired cognitive function. Moreover, 
a recent 10­year longitudinal prospective study found 
that elevated PTH concentrations are associated with a 
five­year cognitive decline in a general aged population, 
although this was found to be independent of calcium 
concentrations[35]. Further investigation would be required 
to establish a common role for calcium as a contributing 
factor to both osteoporosis and cognitive decline. 
Thyroid disease
Overt thyroid disease is well known to be a reversible 
cause of cognitive impairment and altered bone meta­
bolism[36]. Subclinical thyroid disease ­ whereby normal 
levels of thyroxine (T4) and tri­iodothyronine (T3) are 
coupled with a deranged level of thyroid stimulating 
hormone (TSH) ­ is being increasingly recognised as a 
cause of significant morbidity and mortality within the 
elderly population[37]. 
Subclinical hyperthyroidism: Subclinical hyper­
Downey CL et al . Dementia and osteoporosis in a geriatric population
417 May 18, 2017|Volume 8|Issue 5|WJO|www.wjgnet.com
thyroidism (levels of T3 and T4 that are towards the 
top of the reference range coupled with reduced TSH, 
without symptoms of thyrotoxicosis) has been associated 
with various pathologies, and affects both bone mineral 
density and cognition[38]. This may be due to exogenous 
causes, i.e., excessive replacement with levothyroxine 
in hypothyroid patients; or endogenous causes such as 
Grave’s disease[37]. 
There is considerable debate as to whether it is 
the level of TSH or of T4 itself that results in the phy­
siological effects of thyroid hormone excess. A pros­
pective study in Rotterdam found that individuals 
with subclinical hyperthyroidism had a greater than 
threefold increase in risk of developing dementia; with 
higher levels of T4 conferring greater risk. It is worth 
noting that none of these patients had a T4 level above 
the reference range[36]. This finding is supported by a 
further retrospective study, which also demonstrated 
an association between elevated thyroid hormone 
levels and dementia, not related to the concentration of 
TSH. It therefore seems likely that the level of T4 is the 
important determinant[39]. Furthermore, in a prospective 
cohort study of 665 Japanese­American men, followed­
up for development of dementia after thyroid function 
was recorded, subsequent autopsy of one fifth of the 
cohort­including both healthy and demented patients­
demonstrated that at higher levels of T4, more numerous 
intracerebral tangles and plaques are seen, as well as 
clinical dementia[40]. 
Data regarding any association between osteoporosis 
and subclinical hyperthyroidism is unclear. Some studies 
show low levels of TSH appear to result in slightly reduced 
bone mineral density in men and post­menopausal 
women, but the protective effect of oestrogens means this 
does not generally apply in pre­menopausal women[41]. 
The fifth Tromso population study in Norway, conducted in 
2001, compared bone mineral density levels of TSH whilst 
adjusting for possible confounding factors such as weight 
and smoking. It discovered that, if TSH was normal, there 
was no relationship to bone mineral density; however, 
low TSH was seen in subjects with lower bone mineral 
density[42]. T4 levels that are within the normal range are 
correlated with a lower level of bone mineral density at 
both the higher and lower ends of the spectrum ­ that 
is, in the region of subclinical thyroid disease[36,43]. These 
hormone derangements are also associated with increased 
risk of fracture[44]. 
Subclinical hypothyroidism: Subclinical hypothyroidism 
is a significant problem within the elderly population, and 
is more common than overt hypothyroidism[45]. Despite 
the above discussion relating subclinical hyperthyroidism 
to cognitive impairment and dementia, patients with 
subclinical hypothyroidism have also been shown to be 
more likely to develop such attributes[46]. This may be due 
to the effect of T4 itself, or reduced hormone concentration 
within the brain, resulting in slower information processing 
and increased susceptibility to cognitive dysfunction[47]. It 
is also worth noting that treatment with levothyroxine has 
been shown to reduce cognitive impairment and improve 
mood in patients with mild hypothyroidism[48]. Currently, 
although there is evidence that both states can cause 
cognitive decline, subclinical hyperthyroidism appears 
to have a stronger association with the development of 
dementia. A small scale study of 59 patients with multi­
diagnosis dementia found a slight increase in TSH serum 
levels patients with AD compared to other diagnosis 
dementia patients and with healthy controls, along with 
a decrease in cerebrospinal fluid (CSF) total T4 levels in 
both patients with AD and those with other diagnoses 
compared to healthy controls[49]. The CSF total T4 levels 
correlated positively with MMSE test scores and negatively 
with markers of axonal damage, which the authors 
hypothesized may mean that central levels of T4 are 
functionally important in AD[49]. 
Despite the association between subclinical hypo­
thyroidism and cognitive impairment, osteoporosis has 
not specifically been linked to subclinical hypothyroidism. 
Overtreatment of these patients with thyroxine has in fact 
been shown to lead to reduced bone mineral density and 
an increased rate of osteoporosis[50,51]. This represents 
an important clinical disadvantage, and clinicians should 
exert caution in deciding whether or not to treat subclinical 
hypothyroidism[51]. Subclinical thyroid disease is common 
in the elderly population, and has been shown to be 
associated with a number of co­morbidities including 
osteoporosis and dementia in the case of subclinical 
hyperthyroidism. Additional work is required to establish 
if age­related changes in thyroid hormone concentrations 
represent a common factor in the aetiology of both 
conditions. Furthermore, investigating the treatment 
of subclinical disease, and whether or not it results in a 
lower rate of dementia and osteoporosis in the elderly, 
represents an exciting avenue for research in the future.
Alcohol
Excessive alcohol use is well known to result in low bone 
mineral density and increased risk of fracture[52]. This has 
been thought to be due to a direct deleterious effect on 
osteoblast activity and subsequently a decrease in bone 
formation[53], however this mechanism is not likely to be 
related to the development of dementia. Recently it has 
been suggested that lower levels of vitamin D in chronic 
alcoholics may be related to hepatic insufficiency and 
subsequently impaired metabolism of the substance[54]. 
This could in turn affect bone formation. It must be 
remembered that low to moderate levels of alcohol 
intake does not reduce bone density; however, there has 
been no protective effect demonstrated either.
Whilst chronic excessive alcohol use leads to unique 
forms of dementia (i.e., Korsakoff’s syndrome) this is 
secondary to vitamin deficiencies, especially thiamine. 
Ethanol toxicity has been shown in rats to cause hippo­
campal and cortical cell loss, as well as loss of proteins 
required for neuronal survival[55]. However, at low to 
moderate levels of intake there appears to be a protective 
effect against developing dementia[56,57]. Interestingly, 
there was no protective effect seen in individuals with the 
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APOE4 gene[56]. The reasons for this protective effect are 
currently unclear.
It is difficult to assess whether alcohol intake is related 
to an increased risk of osteoporosis and dementia, 
especially given the likely protective effect of a moderate 
alcohol intake against dementia. The multiple comor­
bidities often experienced by chronic alcoholics (most 
notably nutrient deficiency) means studies are affected 
by a number of confounding factors. Varying patterns in 
form and frequency of alcohol abuse also make analysis 
difficult. Any link that were to be demonstrated would 
possibly be due to a secondary impact on another aspect 
of physiology (such as vitamin D deficiency), as opposed 
to an innate property of ethanol itself.
Statins
Statins (HMG CoA reductase inhibitors) are currently 
the target of a large volume of research given their 
supposed pleiotropic effects. As well as treating dys­
lipidaemia, statins have been proposed as being effective 
against malignancy, nephropathy, cataract formation and 
macular degeneration as well as against osteoporosis 
and dementia[58]. 
The role of statins in reducing the risk of dementia 
was classically thought to be due to their role in reducing 
plaque formation, hence reducing vascular insults to 
the brain and the risk of ischaemic neuronal loss[59]. 
Newer studies have proposed a systemic reduction in the 
inflammatory response, as evidenced by the ability of 
statins to reduce levels of C­reactive protein[60]. Statins 
act on the mevalonate pathway, inhibiting conversion of 
HMG­CoA to mevalonate[61]. Mevalonate is a precursor of 
the interleukin­6 group of cytokines which are implicated 
in systemic inflammation[60]. It is possible that a reduction 
in systemic inflammation by inhibiting this pathway may 
help to prevent the development of dementia[62].
Given the interest in the proposed mechanisms, 
Cochrane reviews have been held into randomised 
controlled trials of both the prevention and treatment 
of dementia by statins. They have found that despite 
marked reductions in serum low density cholesterol 
levels, statin use neither improves cognitive function in 
those with dementia nor does it reduce the incidence. 
The reviews conclude that there is insufficient evidence 
to recommend statins as either a prophylactic against, or 
treatment for, dementia[63,64].
New theories on the development of osteoporosis hold 
that the mechanism is similar to that whereby lipids are 
oxidised[65]. If statins were shown to act directly on this 
mechanism then a beneficial effect in osteoporosis would 
also be likely. In vitro studies investigating mechanisms 
by which statins stimulate osteoblast differentiation have 
demonstrated that they exert their effects via the SMAD 
and the bone morphogenetic protein­2 (BMP­2) signalling 
pathways[66]. A recent review of in vitro and in vivo data 
suggests that statins also act via the RANKL pathway, 
which has been implicated in both adipogenesis and in 
changing osteoclastic activity, leading to osteoporosis[67].
Whilst there are theoretical benefits of statins in 
both dementia and osteoporosis, they have yet to be 
demonstrated in clinical studies. A large meta­analysis of 
hip bone mineral density showed a small but statistically 
significant benefit in patients taking statins[68]. However, 
this advantage does not translate into a decreased risk 
of fracture, according to a systematic review of studies 
observing fracture incidence in patients taking statins[69]. 
A recent RCT has also failed to demonstrate the benefit 
of specific statins in decreasing fracture risk[70]. Further 
evidence is required before routine statin use can be 
recommended for the prevention or treatment of either 
condition.
Androgens and oestrogens
Sex steroids play important roles in reproductive function, 
and in recent years receptors for these hormones have 
been identified in a range of body tissues, including bone 
and the nervous system[71]. The relationship between 
ageing, falling levels of sex steroids, and the subsequent 
reduction in bone mineral density is well described and 
a cause of much morbidity in the elderly population. 
Reduction in oestrogen levels in women is known to result 
in increased osteoclast activity and bone resorption[72]. The 
androgens are also known to be important in maintaining 
bone mineral density, both through intrinsic activity and 
as a result of aromatization to oestrogens[73]. Androgen 
activity gradually reduces in later male life, hence the 
resulting increase in rates of osteoporosis in older men. 
Whilst administration of endogenous sex steroids in 
the form of hormone replacement therapy in post­
menopausal women does reduce the risk of fracture, it is 
no longer recommended for the prevention of osteoporosis 
due to cardiovascular side­effects[74]. Newer theories 
propose that oxidative stress holds an important role in 
the development of osteoporosis, and that sex steroids 
are important in protecting against this[65]. This would 
represent a possible therapeutic target with statin agents, 
if such a mechanism is proven.
Androgens and oestrogens have been suggested 
as being protective against AD, given that cognitive 
impairment is associated with a decrease in testosterone 
levels[75]. Animal studies have shown increased neuronal 
activity when testosterone supplements are administered, 
but the data from clinical trials is disappointingly incon­
clusive[75]. Additionally, the role of oestrogen in both 
preventing cognitive decline in intellectually normal 
women, and in maintaining cognitive function in patients 
with AD, has been the subject of a number of systematic 
reviews. Insufficient evidence for any beneficial effect 
was found for oestrogen administration in all studies 
reviewed[76,77]. Moreover, one review of long­term hor­
mone replacement therapy found that in healthy women 
aged over 65 there was an increased incidence of 
dementia[74], although this is unlikely to be due to a direct 
effect of hormone replacement, and may simply be a 
result of an increase in frequency of cardiovascular events, 
a known independent risk factor for developing dementia. 
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There has been recent animal work looking at the effects 
of sex steroid analogues, so called selective androgen 
receptor agonists (SARMs) and selective estrogen 
receptor agonists, which are thought to allow for the 
beneficial effects of the sex steroids in protecting against 
neurodegenerative disorders whilst avoiding detrimental 
cardiovascular tissue effects which may also contribute to 
development of dementia[78]. Such analogues are thought 
to interfere in the progression of AD by aiding clearance 
of amyloid beta peptides from neurological tissue[78]. In 
the treated mice there were decreased levels of amyloid 
beta, along with increased levels of amyloid beta clearing 
enzymes and improved long term memory[78]. 
The evidence surrounding changes in sex steroid levels 
and dementia is inconclusive. There is no firm evidence 
for a beneficial effect of androgen administration, and 
the increase in frequency of cardiovascular events causes 
significant morbidity and may increase the prevalence 
of dementia itself. This may be due to the significant 
increase in cholesterol levels associated with falling 
androgen levels[79]. Additionally, the low levels of androgens 
demonstrated in some men with dementia may be un­
related or may be secondary to the disease itself.
DISCUSSION
Despite various possible mechanisms for a link between 
the two pathologies, it is also quite possible that these 
associations are coincidental and not related to a 
common aetiological factor. Only one such investigation 
into common aetiologies exists in a 2014 study which 
found raised amyloid beta peptide levels in osteoporotic 
bone tissue compared to age matched controls in 
female patients[80]. The level of amyloid beta expression 
negatively correlated with bone density levels in this 
study[80]. Amyloid beta was found to also have an 
impact on osteoclast differentiation and activation, 
implying it may play a role in the pathological processes 
of osteoporosis[80]. Authors hypothesized amyloid beta 
disorders to be systemic disorders resulting in differing 
tissue manifestations[80], yet robust evidence remains to 
be produced regarding this link and regarding the exact 
aetiology of amyloid beta in AD. 
People with dementia are more prone to falls and 
fractures due to cognitive and behavioural disorders, 
visual and motor problems, gait and balance disturbances, 
malnutrition, and the adverse effects of medication[81]. 
Thus there may be a higher pick­up rate for osteoporosis 
amongst this group. However, a population­based study 
of more than 2600 elderly people found that those 
with dementia received less preventative treatment for 
osteoporosis compared to people without dementia[82]. In 
patients who have received the appropriate prescription, 
efficacy may be diminished in patients with dementia due 
to factors such as medical comorbidities, polypharmacy, 
lack of adherence, substance abuse, delirium and 
inadequate social support[83]. 
Nevertheless, we hypothesise that dementia and 
osteoporosis have common aetiologies as significant 
counterevidence exists in recent literature. There remains 
a significant increased prevalence of osteoporosis in AD 
sufferers in large scale observational studies compared 
to the general population, with an odds ratio for femoral 
fracture amongst a French female population the same 
as that of other severe systemic illnesses (OR = 4, P < 
0.0001). The mortality and morbidity associated with 
such fractures in elderly populations prompts continued 
interest in this area of research[84]. Furthermore, following 
femoral neck fracture treatment and subsequent inpatient 
stays, this subsection of the population has been found 
to have poor return to previous functional states as 
measured by residential status, along with poor 30­d 
mortality compared to patients without dementia[85]. 
Other very large scale observational studies have had 
compelling results in favour of a potential link, with 
Chang et al[86] finding a 1.46­fold and 1.39­fold higher 
risk of dementia (95%CI: 1.37­1.56) and AD (95%CI: 
0.95­2.02) in osteoporosis patients studied, whilst 
adjusting for potential confounders such as comorbid 
disease. This Taiwanese cohort also demonstrated a 
negative correlation between treatment for osteoporosis 
(such as bisphosphonates) and the risk of dementia, with 
the most marked negative correlation found in those 
taking bisphosphonates and oestrogens[86]. However, 
patients with dementia have repeatedly been found to 
be least likely to be prescribed osteoporosis treatments 
which may have such protective effects both in terms 
of fracture risk and cognitive health[87]. Despite these 
recent findings, the same limitations to such large scale 
retrospective studies apply and further RCTs would be 
required to provide higher quality evidence of such links 
despite the varied evidence explored in this paper. 
The most compelling evidence for a common aetio­
logy is the APOE4 allele, a major cholesterol carrier, 
and a well­established genetic risk factor for AD via its 
binding to Amyloid beta peptide and its potential role 
in deposition of senile plaques[3]. APOE4 has also been 
found to be associated with fracture, independent of 
dementia and falling[27]. The mechanism behind this 
effect on fracture risk is postulated to be the reduced 
plasma vitamin K levels in individuals exhibiting the 
APOE4 allele, which binds vitamin K in the plasma and 
promotes its uptake into the liver more rapidly than 
other APOE variants. Women who express this allele 
have a higher risk of osteoporotic fractures than other 
APOE genotypes found in the general population[1]. This 
may be multifactorial in its effect and augmented by the 
nutritional deficiencies associated with dementia, which 
are known to include vitamins K and D. In particular, 
vitamins D and K are known to play a role in the both 
bone matrix stability and neuronal protection in the CNS. 
The vitamin theory postulates that malnutrition and 
reduced exposure to sunlight in patients with AD leads to 
vitamin deficiencies.
Robust evidence of an underlying pathophysiological 
link between osteoporosis and dementia would potentially 
transform the care of the older adult. Research to date 
has tended to be fragmented and of a relatively weak 
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nature with multiple confounding factors reflecting the 
difficulties of in vivo experimentation in the population 
of interest. A suggestion for future work would include 
randomised controlled trials of vitamin supplementation 
vs placebo, stratified for APOE4 and hormone status. As 
our understanding of the molecular basis of osteoporosis 
and dementia improves, new therapeutic targets should 
become apparent.
COMMENTS
Background
Dementia and osteoporosis are diseases processes with similar epidemiology 
and increasing prevalence in the elderly, where the two coexist in a subsection 
of the population especially amongst females. The burden of elderly care 
continues to be a significant challenge to healthcare systems globally. 
Alzheimer’s disease (AD) is the leading cause of loss of independence and 
autonomy in the elderly and osteoporotic fractures have a huge impact in 
this patient population in terms of morbidity and mortality. An odds ratio of 
6.9 for fracture prevalence between people with and without AD has been 
reported. In current understanding of the disease aetiologies no pathological 
overlap has been identified but a common link has been postulated to exist. 
The pathogenesis of AD is currently understood to involve development of 
amyloid plaques causing neuronal death and subsequent phosphorylation 
of Tau proteins, which ultimately cause further neuronal degeneration and 
the localisation of these two abnormal proteins in the synapses causes post-
synaptic neuronal death via calcium influx. Despite extensive research into AD 
and its multifactorial pathophysiology, current treatments are limited by cost and 
efficacy and their action lies in palliation of symptoms. Osteoporosis in contrast 
is a progressive skeletal disease characterised by reduced bone density and 
micro-architectural bone destruction leading to increased susceptibility to 
fracture. Both diseases have multifactorial pathophysiology and have been 
associated with other metabolic disturbances including decreased vitamin D 
levels and elevated parathyroid hormone. Other genetic variants such as the 
APOE4 allele have also been postulated to link their pathophysiology.
Research frontiers
Both osteoporosis and AD form part of frailty syndrome, a collection of signs 
and symptoms associated with significant disability in the elderly population 
and increased public expenditure in healthcare and social care systems. This 
paper hypothesizes that both diseases share a common predisposing aetiology, 
which may be multifactorial and involve genetic, metabolic, endocrine and 
environmental factors. 
Innovations and breakthroughs
Many studies have been conducted in the last 60 years exploring various aspects 
of the pathophysiology of both osteoporosis and dementia as both diseases 
represent significant burdens upon the affected populations. However very few 
have been higher tier research designs such as randomised control trials or 
specifically examined an aetiological link as addressed by the research question 
of this paper. The authors’ key findings were that the most compelling evidence 
of a common yet independent aetiology lies in the APOE4 allele, which is a well-
established risk for AD but also carries an independent association with fracture 
risk and so osteoporosis. The mechanism behind this is thought to be the reduced 
plasma vitamin K levels in individuals exhibiting the APOE4 allele which may 
be amplified by the nutritional deficiencies associated with dementia, which are 
known to include vitamins K and D. The vitamin theory postulates that malnutrition 
and reduced exposure to sunlight in patients with AD leads to vitamin deficiencies 
which are then well associated with increased risk of fracture. 
Applications
Discovery of a common aetiological link between the two may prove key 
in development of novel treatments for these complex medical and social 
problems. This study found that research to date on this topic has tended 
to be fragmented and of a relatively weak nature with multiple confounding 
factors, which may reflect inherent difficulties of in vivo experimentation in the 
population of interest. Despite many theoretical links between the two diseases, 
there is a lack of systematic high level evidence and as such the link between 
the two remains theoretical. This study may help direct design of future large 
scale studies or RCTs in the affected population groups. 
Peer-review
This is an interesting study, and what is reviewed is well done.
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